CDER/CBER Consolidation: Drug Center Structure Is Not Expected To Change
Executive Summary
The Center for Drug Evaluation & Research expects that the assumption of product review responsibilities for biological products can be accomplished within its existing organizational framework
You may also be interested in...
Rx Withdrawals: FDA, GAO Differ On Whether Recent Increase Is “Real”
The prescription drug withdrawal rate has not shown a "real" increase since the implementation of the Prescription Drug User Fee Act, FDA declared in response to a Government Accounting Office report
Rx Withdrawals: FDA, GAO Differ On Whether Recent Increase Is “Real”
The prescription drug withdrawal rate has not shown a "real" increase since the implementation of the Prescription Drug User Fee Act, FDA declared in response to a Government Accounting Office report
FDA Fast Track, Priority Review Policies For Vaccines Need Expansion – GAO
GAO is recommending that FDA revise its fast track and priority review approval policies to allow shorter reviews for vaccines even in the absence of a shortage